What happened
EuBiologics reported separate results for FY2025: revenue of US$103M (+55.4% year on year), operating profit of US$41.9M (+76.8% year on year) and net income of US$33.6M (+156.4% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$103M |
|---|---|
| Revenue vs a year earlier | +55.4% |
| Operating profit | US$41.9M |
| Net income | US$33.6M |
| Period | FY2025 (separate) |
| Filed | 2026-02-02, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260202901622 → open original filing |
Source: DART. Information only, not investment advice.